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There is an urgent need for early diagnosis in medicine, whereupon eﬀective treatments could prevent irreversible tissue damage.
The special structure of the eye provides a unique opportunity for noninvasive light-based imaging of ocular fundus vasculature.
To detect endothelial injury at the early and reversible stage of adhesion molecule upregulation, some novel imaging agents
that target retinal endothelial molecules were generated. In vivo molecular imaging has a great potential to impact medicine by
detectingdiseasesorscreeningdiseaseinearlystages,identifyingextentofdisease,selectingdiseaseandpatient-speciﬁctherapeutic
treatment, applying a directed or targeted therapy, and measuring molecular-speciﬁc eﬀects of treatment. Current preclinical
ﬁndings and advances in instrumentation such as endoscopes and microcatheters suggest that these molecular imaging modalities
have numerous clinical applications and will be translated into clinical use in the near future.
1.Introduction
The use of visible light to examine intraocular processes
can be considered the traditional form of imaging in
ophthalmology. Molecular imaging permits noninvasive
visualization and measurement of molecular and cell biology
in living subjects, thereby complementing conventional
anatomicalimaging.Opticalmolecularimagingtechnologies
use light emitted through ﬂuorescence or bioluminescence.
Molecular imaging is deﬁned as the ability to visualize and
quantitatively measure the function of biological and cellular
processes in vivo [1, 2], while anatomical imaging plays a
major role in medical imaging for diagnosis, surgical guid-
ance, and treatment monitoring, focused and personalized
therapy, and earlier treatment followup. The main advantage
of in vivo molecular imaging is its ability to characterize
pathologies of diseased tissues without invasive biopsies or
surgical procedures, and with this information in hand,
a more personalized treatment-planning regimen can be
applied.
In vivo visualization techniques of the retinal microcir-
culation, including conventional fundus ﬂuorescein angiog-
raphy (FFA) and indocyanine green angiography (ICGA)
or the experimental laser-targeted angiography [3, 4], are
used to investigate the retinal vascular network and hemo-
dynamic conditions [5]. However, these methods do not
allow evaluation of leukocyte endothelial interaction in the
retinal ﬂow or identiﬁcation of speciﬁc molecular changes
duringdisease.Recently,weintroducedanoveltechniquefor
detection of endothelial surface molecules in ocular inﬂam-
mation [6]. Using adhesive molecule-conjugated ﬂuorescent
microspheres (MSs) [7] in live animals, we showed early
endothelial changes in ocular microvessels at an early stage,
which were previously detectable only by the most sensitive
in vitro techniques, such as immunohistochemistry or PCR
[6]. In ﬂuorescence imaging, light of the excitation wave-
lengths must penetrate tissues to reach a targeted reporter
molecule carrying a ﬂuorochrome, resulting in the emission
oflightofusuallylowerwavelengththatcanberegisteredbya
charge-coupled device (CCD) camera. Fluorescent proteins,
such as cyan, green, or yellow ﬂuorescent protein, can be
introduced into cells of choice by transgenic technology. For
accurate in vivo detection and measurement, these novel
tools provide high speciﬁcity for their target.
This paper brieﬂy describes diﬀerent molecular imaging
techniques and devices used in retinal imaging, as well as2 Journal of Ophthalmology
potential imaging tools and targets that may be translated
into clinical applications in the near future.
2. Historyof Molecular Imaging
The development of molecular imaging is rooted in radiol-
ogy and nuclear medicine as well as in molecular biology.
Since the 1950s, nuclear imaging of radioactive isotope-
labeled biomacromolecule has been an integral part of drug
development and diagnostic imaging. The broad clinical
signiﬁcance of such approaches remained restricted until
positron emission tomography was introduced in 1979 and
became an important tool for the detection of metabolic
activities in tissues such as the brain and heart, as well as
in cancer. It facilitated a biological imaging readout, albeit
with limited speciﬁcity. Around the same time, magnetic
resonancespectroscopypromotedtheevolutionofmolecular
imaging. The ability to collect information about speciﬁc
endogenous molecules by taking advantage of their intrinsic
nuclearspinpropertyrepresentedanearlyexampleofmolec-
ular imaging. These advances paved the way for pioneering
molecular imaging studies by demonstrating in vivo imaging
of reporter gene expression [8]. Concurrently, optical biolu-
minescenceimagingforinvivodetectionoftheFLucreporter
gene was demonstrated [9]. Taken together, these studies
propelledmolecularimagingintothescientiﬁcspotlight.The
introduction of imaging instrumentation dedicated to small
animals [10] and the description of enzyme-activated small-
molecule probes for optical ﬂuorescence imaging further
fueledscientiﬁcinterest[11].Recentworkhasfocusedonthe
extension and reﬁnement of molecular imaging technology
and its application to the diagnosis of cancer [12]a n d
cardiovascular disease [13]. Molecular imaging has started




The use of visible light to examine intraocular processes can
be considered the oldest form of imaging in ophthalmology.
The unique optical properties of the eye allow direct
microscopic observation of the retina. Optical molecular
imaging technologies use light emitted through ﬂuores-
cence or bioluminescence. In ﬂuorescence imaging, light
of the excitation wavelengths must penetrate tissues to
reach a targeted reporter molecule carrying a ﬂuorochrome,
resulting in the emission of light of usually lower wave-
length that can be registered by a charge-coupled device
(CCD) camera. Fluorescent proteins, such as cyan, green,
or yellow ﬂuorescent protein can be introduced into cells
of choice by transgenic technology. This technology has
greatly facilitated studies on GFP-positive animals. These
animals render all cells expressing the fractalkine receptor,
such as microglia cells, dendritic cells, and macrophages,
intrinsically ﬂuorescent [16]. Certain ﬁlters, such as those
used by ﬂuorescein or indocyanine green angiography, allow
the detection of speciﬁcally ﬂuorescent structures. As in
ﬂuorescence imaging, numerous transgenic animals have
been generated that express various types of luciferase under
diﬀerent promoters whose expression in disease models can
be measured after ﬂorescence injection. Imaging stations
have been developed that allow detection of even faint light
emission from within the body of experimental animals.
This method is particularly helpful when long emission
wavelengths are employed, because these penetrate living
tissues much better. Noninvasive time-course analyses have
therefore become possible and could theoretically be of
great use in ophthalmology as well as in other ﬁelds.
Inﬂammation and tracing of inﬂammatory cells has been
a key topic in molecular imaging in recent years. Using
an established model of ocular inﬂammation, endotoxin-
induceduveitis,Sunandcolleaguesvisualizedtherollingand
adhesive interaction of ﬂuorescent microspheres conjugated
to recombinant P-selectin glycoprotein ligand-Ig (rPSGL-
Ig) in the choriocapillaris by means of SLO. In our recent
work [17], we further introduce novel molecular imaging
agents that target two distinct types of endothelial surface
molecules, a mediator of rolling and one that mediates ﬁrm
adhesion, and evaluate the success of anti-inﬂammatory
treatment in vivo.
Our imaging approach is founded on certain aspects
of leukocyte-endothelial interaction, a common component
in the pathogenesis of various ocular diseases. Leukocytes
normally do not interact with the endothelium of blood
vessels, save for occasional tethering. However, at sites of
inﬂammation, endothelial cells express adhesion molecules,
such as P-selectin and intercellular adhesion molecule-1
(ICAM-1) which facilitate the multistep leukocyte recruit-
ment cascade [18]. The steps of the recruitment process
include tethering, rolling, ﬁrm adhesion, and transmigration
into the extravascular space [7, 19]. Leukocyte rolling is
mediated mainly through transient interaction of selectins
with their ligands. Our results show the superior sensitivity
ofdouble-conjugatedMSsfordetectionofendothelialinjury,
compared to MSs that only target one type of endothe-
lial markers. Our previous work showed accumulation of
rPSGL-1-conjugated MSs in choroidal microvessels [6].
Here, we also quantitatively compare the rolling of various
MSs in retinal and choroidal vessels. The rolling ﬂux of
rPSGL-1-conjugated MSs is signiﬁcantly higher in EIU
animals than in controls. In contrast, the rolling ﬂux of
anti-ICAM-1-conjugated MSs is not signiﬁcantly diﬀerent
between EIU and control animals. This ﬁnding is in line with
the fact that CD18/ICAM-1 is not primarily a rolling ligand
pair in vivo. The signiﬁcantly higher rolling interaction
of the double-conjugated MSs compared to the rPSGL-
1-conjugated MSs indicates that ICAM-1 may contribute
to the rolling of the MSs, once the interaction with the
endothelium is initiated. Surprisingly, the rolling velocity
of the double-conjugated MSs is signiﬁcantly higher in the
choroidal vessels than in the retina. The absolute number
of MS interactions in the choriocapillaris is higher than in
the retina. This diﬀerence might be explained by the higher
vascular density in the choriocapillaris compared to the
retina. Also, the inﬂammatory response in the choroid may
diﬀer from retina. Another striking qualitative diﬀerence
between the two vascular beds is that, in the retina, mostJournal of Ophthalmology 3
rolling initiates from the periphery and continues toward
the optic nerve head, suggesting that the rolling interaction
mainly occurs in the retinal veins.
Acridine orange digital ﬂuorography revealed leucocyte
rolling in the retina of animals with experimental autoim-
mune uveoretinitis. Acridine orange solution was injected
continuously through a tail vein at a proper velocity. Retinal
images were generated by an SLO connected to a computer-
assisted image analysis system. Acridine orange binds to
DNA and RNA, and the spectral properties of acridine
orange DNA complexes are very similar to those of sodium
ﬂuorescein, with a 502nm excitation maximum and an
emission maximum of 522nm. Results reveal that leukocyte
endothelium interaction and extravascular inﬁltration in the
retinal venous vasculature may play signiﬁcant roles in the
early stages of posterior segment inﬂammation.
Xu and colleagues reported another method of investi-
gatingleucocytesintheretinalvasculaturebySLO.Theytried
to inject calcein-acetoxymethyl ester- (AM-) labeled T cells
into the tail vein of rodents [20]. Leucocyte dynamics can
also be monitored in the iris stroma, limbus, and choroid
using intravital microscopy with an epiﬂuorescent illumina-
tion microscope equipped with a black-and-white camera
connected to a video capture card. Leucocytes were stained
either with rhodamine G66 or carboxy ﬂuorescein diacetate
succinimidyl ester (CFSE) to monitor the iris and limbus to
v i s u a l i s el e u c o c y t e si nt h ec h o r o i d[ 21]. Interleukin- (IL-) 2,
which is expressed upon stimulation of T cells, commonly
serves as T-cell activation marker. Becker and colleagues
used enhanced GFP as a reporter gene for IL-2 expression.
They showed by intravital microscopy that transgenic mice
expressingGFPunderthecontrolofIL-2regulatoryelements
can be used for in vivo expression assays that allow detection
of activated T cells in the iris at multiple time points
withinthesameanimalwithexperimentaluveitis.Transgenic
reporter mice for numerous other cytokines exist. Intravital
microscopy has also been used for imaging dendritic cells
in the cornea using transgenic mice that express YFP under
control of the CD11c promoter (CD11c-YFP) [22]. cSLO
has also been used to visualise apoptosis of single nerve
cells in the retina in vivo, in order to perform longitudinal
studies of disease processes such as glaucoma [23]. This
technique enables direct observation of single nerve cell
apoptosis by using Alexa Fluor 488-labelled annexin V and
a prototype Zeiss. Further developments in cSLO technique
yielded in vivo retinal images at a cellular level. Adaptive
optics SLO was used to image the retinal pigment epithelial
(RPE) cells in patients with rod-cone dystrophy and bilateral
progressive maculopathy [24]. “Adaptive optics” denotes a
set of methods for measuring and compensating for the
aberration of individual eyes, consisting of trial lenses to
correct sphere and cylinder, a Shack-Hartmann-based wave
front sensor to detect residual aberration, and a deformable
mirror to correct this residual aberration. Integrated into an
SLO, lateral resolution of 2mm could be achieved, which
enables imaging of RPE cells, cone photoreceptors [25], and
the ﬂow of single leucocytes and the lamina cribrosa [26].
Choi and coworkers have integrated adaptive optics into a
fundus camera for imaging cone photoreceptors in patients
with retinal dystrophies and optic neuropathy [27].
4. PreclinicalDevelopments in
MolecularImaging
Preclinical molecular imaging in small animals is an invalu-
able part of new molecular targets and contrast agents,
as well as developing drugs prior to clinical translation
[27]. Research shows that the time intensive and expensive
preclinical steps involved in molecular target identiﬁcation,
validation, chemical synthesis, and characterization for new
molecular imaging agents. In fact, the majority of current
molecular imaging agents used in the clinic were discovered
throughtheseexhaustivepreclinicalexperimentsatacademic
institutions [28]. It is estimated that a molecular imaging
agent costs about $150 million over 10 years to transfer to
the clinic, ending with average double cost per year revenue
for successful contrast agents.
To identify a molecular target beginning with under-
standing and characterizing the biology, the ﬁrst step is to
ﬁnd the diﬀerences between a healthy and diseased state.
For instance, since there is an intricate relationship between
cancer and inﬂammation (chronic inﬂammation maybe
promote, cancer, and cancer onset could promote an inﬂam-
matory response), the diﬀerences between inﬂammation and
cancer states must be characterized. In general, much focus
is directed to cancer imaging including retinal and choroidal
tumor, and several preclinical studies have identiﬁed new
molecular targets for imaging cancer. In addition to imaging
thecancerphenotypesuchasincreasesinmetabolism,angio-
genesis, proliferation, hypoxia, and apoptosis, agents have
been developed to target speciﬁc protein markers expressed
on cancer cells. Many chemotherapeutic drugs also target
these markers; they have been radiolabelled for assessment
of biodistribution and pharmacokinetics using noninvasive
molecular imaging [27]. Continuing preclinical research has
exploded not only in molecular target discovery and imaging
probe developments but also in new strategies for imaging
methodologies, especially in the areas of optical imaging.
With the advent of new, smaller instruments/devices for
insertion into the body, molecular imaging strategies with
optical devices and speciﬁc molecular-targeted contrast
agents have great potential for translation into the clinic,
which is reviewed in the promising sections.
5. Conclusions
Molecular imaging can be applied to all parts of medical
imaging: early detection, screening, diagnosis, therapy deliv-
ery, monitoring, and treatment followup. The current status
of clinical molecular imaging is limited, with most current
applications using visualable imaging and a small number of
highly speciﬁc applications for MRI and ultrasound. Current
demands and trends are calling for new strategies to focus
on early disease detection through improved imaging and
screening protocols in retina, as well as patient-speciﬁc treat-
ment selection delivery and therapy-speciﬁc monitoring. It
is hoped that these new strategies of early diagnosis and4 Journal of Ophthalmology
immediate treatment monitoring will improve success rates
for curing diseases with high mortality rates such as retinal
disease and some types of cancer, as well as providing more
speciﬁc treatment for other diseases. Preclinical research has
resulted in the identiﬁcation of a large number of molecular
targets and the development of novel molecular imaging
contrast agents as well as device, hardware, and software
technologies. It is expected that molecular imaging in retina
withimagingmodalities otherthanourdevelopedMSs,PET,
MRI, molecular ultrasound, and photoacoustic tomography
will be integrated into more frequent clinical application in
the near future.
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